Related Experiment Video
Updated: May 5, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Effect of pitavastatin on preventing ischemic complications with carotid artery stenting: a multicenter prospective
Katsutoshi Takayama1, Waro Taki, Naoki Toma
1Department of Radiology and Interventional Neuroradiology, Ishinkai Yao General Hospital, 1-41 Numa Yao, Osaka, 581-0036, Japan, takayamaneuroivs@par.odn.ne.jp.
Purpose:
Periprocedural ischemic stroke is one problem associated with carotid artery stenting (CAS). This study was designed to assess whether preoperative statin therapy reduces the risk of periprocedural ischemic complications with CAS.
Methods:
In this prospective study at 11 centers, patients with carotid artery stenosis (symptomatic ≥50%, asymptomatic ≥80%) and a high risk of carotid endarterectomy but without previous statin treatments were divided into two groups by low-density lipoprotein cholesterol (LDL-C) levels. With LDL-C ≥120 mg/dl, the pitavastatin-treated (PS) group received pitavastatin at 4 mg/day. With LDL-C <120 mg/dl, the non-PS group received no statin therapy. After 4 weeks, both groups underwent CAS. Frequencies of new ipsilateral ischemic lesions on diffusion-weighted imaging within 72 h after CAS and cerebrovascular events (transient ischemic attack, stroke, or death) within 30 days were assessed.
Results:
Among the 80 patients enrolled, 61 patients (PS group, n = 31; non-PS group, n = 30) fulfilled the inclusion criteria. New ipsilateral ischemic lesions were identified in 8 of 31 patients (25.8%) in the PS group and 16 of 30 patients (53.3%) in the non-PS group (P = 0.028). Cerebrovascular events occurred in 0 patients in the PS group and in 3 of 30 patients (10.0%) in the non-PS group (P = 0.071). Multivariate analyses demonstrated the pitavastatin treatment (β = 0.74, 95% confidence interval 0.070-1.48, P = 0.042) to be an independent factor for decreasing post-CAS ischemic lesions.
Conclusion:
Pretreatment with pitavastatin significantly reduced the frequency of periprocedural ischemic complications with CAS.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
